uHAPs target areas in tumours that conventional cancer treatments leave behind
OncoTherics' focus concerns the biology of low oxygen areas found in most tumours and the role these "hypoxic micro-environments" play in the resistance and spread of a variety of cancers.
Our solution is to target these areas with a new class of pro-drugs, that are able to penetrate these regions and in combination with conventional therapies, deliver an effective treatment across the whole tumour.
In so doing, we are delivering a clean, targeted solution to one of cancer’s most persistent blind spots.
Opportunity
OncoTherics has developed two novel assets;
- OCT1004 - Phase II ready - Pancreatic Cancer
- OCT1002 - Preclinical phase - Prostate Cancer
The company is currently raising first round funding to progress an exciting clinical trial programme.
Oncotherics Poland S.A. is a beneficiary of the regional operational program of the Małopolskie Voivodeship for the years 2014-2020.
wartość projektu: 19 357 662,37 PLN
wkład funduszy Europejskich: 11 718 069,36 PLN
